About Clinigen Healthcare (LON:CLIN)
Clinigen Group plc operates as a specialty pharmaceutical and services company. Its Clinigen Clinical Trial Services segment supplies and manages commercial medical products for use in clinical studies, including comparator drugs, adjuvant drugs, and rescue therapies. The company's Idis Managed Access segment is involved in the consultancy, development, management, and implementation of managed access programs for biotechnology and pharmaceutical companies. Its Idis Global Access segment provides ethical access to post approval and short-supply medicines, in regions where patients have low or non-existent access to these drugs. The company's Clinigen Specialty Pharmaceuticals segment manufactures and distributes its own and in-licensed specialist, and hospital-only medicines worldwide. It offers Ethyol for reducing the incidence of dry mouth in patients undergoing high dose radiation treatment; Cardioxane, a cardioprotective agent that is used to prevent the cardiotoxicity of anthracycline chemotherapy for patients with advanced or metastatic breast cancer; Savene and Totect, which are used as emergency treatments for extravasation at the site of injection of oncology treatment; and Foscavir, an anti-viral targeting human herpes viruses and is used primarily in bone marrow transplant patients. Its Link Healthcare business distributes pharmaceutical products in South Africa and the Asia-Pacific. The company has a strategic alliance with Cumberland Pharmaceuticals Inc. Clinigen Group plc was incorporated in 2008 and is headquartered in Burton-on-Trent, the United Kingdom.
Industry, Sector and Symbol
Industry Drug Delivery
Sub-IndustryN/A
SectorMedical
SymbolLON:CLIN
CUSIPN/A
Phone+44-1283-495010
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins7.15%
Return on Equity8.14%
Return on Assets4.26%
Miscellaneous
EmployeesN/A
Outstanding Shares122,220,000
Clinigen Healthcare (LON:CLIN) Frequently Asked Questions
What is Clinigen Healthcare's stock symbol?
Clinigen Healthcare trades on the London Stock Exchange (LON) under the ticker symbol "CLIN."
How often does Clinigen Healthcare pay dividends? What is the dividend yield for Clinigen Healthcare?
Clinigen Healthcare declared a dividend on Tuesday, February 27th. Stockholders of record on Thursday, March 22nd will be given a dividend of GBX 1.76 per share on Thursday, April 12th. This represents a dividend yield of 0.2%. The ex-dividend date is Thursday, March 22nd. The official announcement can be viewed at this link. View Clinigen Healthcare's Dividend History.
How were Clinigen Healthcare's earnings last quarter?
Clinigen Healthcare (LON:CLIN) issued its earnings results on Tuesday, February, 27th. The company reported $21.20 earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of $20.30 by $0.90. The business had revenue of $167.80 million for the quarter. Clinigen Healthcare had a net margin of 7.15% and a return on equity of 8.14%. View Clinigen Healthcare's Earnings History.
What price target have analysts set for CLIN?
6 brokerages have issued 12-month price objectives for Clinigen Healthcare's stock. Their predictions range from GBX 970 to GBX 1,360. On average, they expect Clinigen Healthcare's stock price to reach GBX 1,212.17 in the next year. View Analyst Ratings for Clinigen Healthcare.
Who are some of Clinigen Healthcare's key competitors?
Some companies that are related to Clinigen Healthcare include NovoCure (NVCR), Halyard Health (HYH), Heron Therapeutics (HRTX), Global Blood Therapeutics (GBT), Allscripts (MDRX), Portola Pharmaceuticals (PTLA), AnaptysBio (ANAB), Medicines (MDCO), UDG Healthcare (UDG), Aerie Pharmaceuticals (AERI), Patterson Companies (PDCO), Quidel (QDEL), Wright Medical Group (WMGI), Primary Health Care (PRY), Motif (MTFB), Intercept Pharmaceuticals (ICPT), Corcept Therapeutics (CORT) and Myriad Genetics (MYGN).
Who are Clinigen Healthcare's key executives?
Clinigen Healthcare's management team includes the folowing people:
- Mr. Shaun Edward Chilton, CEO & Director (Age 50)
- Mr. Martin Abell, CFO & Director
- Ms. Debra Ainge, Chief Operating Officer
- Mr. Paul Thomas, Chief Technical Officer
- Matt Parrish, Head of Investor Relations
Has Clinigen Healthcare been receiving favorable news coverage?
Headlines about CLIN stock have been trending somewhat positive this week, Accern Sentiment reports. Accern identifies negative and positive news coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Clinigen Healthcare earned a news sentiment score of 0.05 on Accern's scale. They also gave media coverage about the company an impact score of 46.85 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the near term.
How do I buy shares of Clinigen Healthcare?
Shares of CLIN and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
What is Clinigen Healthcare's stock price today?
One share of CLIN stock can currently be purchased for approximately GBX 910.
How big of a company is Clinigen Healthcare?
Clinigen Healthcare has a market capitalization of £1.12 billion.
How can I contact Clinigen Healthcare?
Clinigen Healthcare's mailing address is Pitcairn House Crown Square, First Avenue, STAFFORDSHIRE, DE14 2WW, United Kingdom. The company can be reached via phone at +44-1283-495010.
MarketBeat Community Rating for Clinigen Healthcare (CLIN)
MarketBeat's community ratings are surveys of what our community members think about Clinigen Healthcare and other stocks. Vote "Outperform" if you believe CLIN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CLIN will underperform the S&P 500 over the long term. You may vote once every thirty days.
Clinigen Healthcare (LON:CLIN) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
6 Wall Street analysts have issued ratings and price targets for Clinigen Healthcare in the last 12 months. Their average twelve-month price target is GBX 1,212.17The high price target for CLIN is GBX 1,360 and the low price target for CLIN is GBX 970. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 2.83 | 2.83 | 2.83 | 2.75 |
| Ratings Breakdown: | 0 Sell Rating(s)
1 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | GBX 1,212.17 | GBX 1,222.17 | GBX 1,222.17 | GBX 1,078.75 |
Clinigen Healthcare (LON:CLIN) Consensus Price Target History
Clinigen Healthcare (LON:CLIN) Analyst Ratings History
Show:
(Data available from 4/23/2016 forward)
Clinigen Healthcare (LON:CLIN) Earnings History and Estimates Chart
Clinigen Healthcare (LON CLIN) Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 2/27/2018 | S1 2018 | GBX 20.30 | GBX 21.20 | | £167.80 million | View | N/A |  |
| 9/28/2017 | Y 2017 | GBX 41.20 | GBX 41.80 | | £302.30 million | View | N/A | |
(Earnings results data provided by Zacks Investment Research)
Clinigen Healthcare (LON:CLIN) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
| 2/27/2018 | | GBX 1.76 | 0.2% | 3/22/2018 | 3/22/2018 | 4/12/2018 |
| 9/28/2017 | | GBX 3.40 | 0.32% | 11/9/2017 | 11/9/2017 | 12/1/2017 |
| 3/15/2017 | | GBX 1.60 | 0.2% | 3/23/2017 | 3/23/2017 | 4/13/2017 |
| 9/28/2016 | | GBX 2.70 | 0.38% | 11/3/2016 | 11/3/2016 | 11/25/2016 |
| 3/2/2016 | | GBX 1.30 | 0.2% | 3/17/2016 | 3/17/2016 | 4/8/2016 |
| 9/22/2015 | | GBX 2.30 | 0.32% | 10/15/2015 | 10/15/2015 | 11/6/2015 |
| 9/24/2014 | | GBX 2.10 | 0.46% | 10/16/2014 | 10/16/2014 | 11/7/2014 |
| 2/26/2014 | | GBX 1 | 0.19% | 3/5/2014 | 3/5/2014 | 3/28/2014 |
(Data available from 1/1/2013 forward)
Clinigen Healthcare (LON CLIN) Insider Trading and Institutional Ownership History
Clinigen Healthcare (LON CLIN) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 11/23/2017 | Chris Rigg | Insider | Sell | 4,955 | GBX 1,017 | £50,392.35 | | |
| 10/13/2017 | Shaun Edward Chilton | Insider | Sell | 100,000 | GBX 1,150 | £1,150,000 | | |
| 10/2/2017 | John Bacon | Insider | Sell | 250,000 | GBX 1,093 | £2,732,500 | | |
| 6/28/2017 | John Bacon | Insider | Sell | 200,000 | GBX 843 | £1,686,000 | | |
| 6/22/2017 | Peter George | former CEO | Sell | 500,000 | GBX 875 | £4,375,000 | | |
| 11/11/2016 | John Bacon | Insider | Sell | 200,000 | GBX 717 | £1,434,000 | | |
| 10/18/2016 | Shaun Edward Chilton | Insider | Sell | 97,246 | GBX 750 | £729,345 | | |
| 5/16/2016 | Abell,Martin | Insider | Buy | 11,296 | GBX 518 | £58,513.28 | | |
| 10/7/2015 | Edward Chilton,Shaun | Insider | Sell | 412,778 | GBX 685 | £2,827,529.30 | | |
| 6/3/2015 | John Hartup | Insider | Sell | 23,934 | GBX 644 | £154,134.96 | | |
(Data available from 1/1/2013 forward)
Clinigen Healthcare (LON CLIN) News Headlines
| Source: |
|
Clinigen Healthcare (LON:CLIN) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Financials are not available for this stock.
Clinigen Healthcare (LON CLIN) Stock Chart for Monday, April, 23, 2018
Loading chart…
